LONZA GROUP AG 2026 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance: Lonza delivered a strong H1 2026 with sales of CHF 3.4 billion, up 16% CER organically, and CORE EBITDA of CHF 1.2 billion with a 34.8% margin, up 4.4 points year over year. Free cash flow improved significantly to CHF 426 million from CHF 116 million in H1 2025. By platform, Integrated Biologics grew 10% CER with a 36% margin, Advanced Synthesis grew 27.7% CER with a 48.1% margin, and Specialized Modalities grew 22.6% CER with a 28% margin. FX was a headwind in H1, but management expects it to moderate in H2.

Company Outlook & Strategy: Management upgraded full-year 2026 CORE EBITDA margin guidance to 33%-34% from above 32%, while reaffirming 11%-12% CER sales growth. The company emphasized disciplined execution of the One Lonza strategy and transformation into a pure-play CDMO, supported by a strong capital allocation framework. Lonza plans to invest more than CHF 7 billion in organic CapEx through 2030, focused on growth projects with at least 15% IRR and 30% peak ROIC. Management reiterated confidence in a long-term low-teens organic sales growth model with expanding profitability and cash generation.

Key Industry Trends: The call highlighted sustained demand for outsourcing across biopharma, with mammalian capacity still outpacing supply. Geo-political developments are increasing customer interest in U.S. manufacturing capacity and regionalized supply chains, which supports Lonza’s global footprint. Management noted no fundamental shift in customer willingness to outsource, and said strategic partnerships remain strong across large pharma and biotech. Demand is especially strong in biologics, cell and gene, and ADC-related capabilities.

Operational Highlights: Lonza reported strong operational execution, better productivity, and cost discipline across the network. Major growth projects continued to ramp, including Vacaville CDMO readiness upgrades, Visp mammalian capacity, and Stein drug product expansion. New investments were announced for ADC payload-linker manufacturing in Visp and a second commercial ADC fill-finish line in Stein, with an anchor customer already in place. Specialized Modalities improved materially as microbial returned to growth and cell and gene normalized toward the end of H1. The company also completed the strategic divestment of Capsules & Health Ingredients for CHF 2.3 billion enterprise value, expected to close before year-end 2026.

Challenges & Risks: Management acknowledged FX pressure in H1, though it should ease in H2. CapEx is inherently lumpy, and project timing changes can affect annual phasing and margins. Vacaville will see an H2 shutdown for site upgrades, which lowers near-term sales but is expected to be offset over time. Advanced Synthesis growth and margins are expected to normalize in H2 versus a strong H1 comparison base. Work on working capital remains an opportunity, as trade working capital increased due to higher receivables from strong growth.

Key Analyst Questions & Responses: An analyst asked how Lonza manages changing CapEx programs and whether project timing shifts, such as the Stein fill-finish scope expansion, could affect margin positioning within the medium-term range. Management said CapEx is naturally lumpy and should be viewed within a broader mid-to-high-teens-of-sales corridor rather than year-by-year precision. They stressed that the company has clear long-term visibility on investment timing and capacity needs. Regarding Stein, management said the scope expansion to include high-value small molecules added only a small amount of CapEx but extended the timeline modestly. Overall, they reaffirmed confidence in the company’s low-teens long-term sales growth trajectory.